-
1Academic Journal
Συγγραφείς: S. Ya. Volgina, Ya. S. Kurbanova, R. G. Gamirova, N. A. Solovyeva, G. A. Kulakova, E. A. Kurmayeva, С. Я. Волгина, Е. С. Курбанова, Р. Г. Гамирова, Н. A. Соловьева, Г. А. Кулакова, Е. А. Курмаева
Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 70, № 5 (2025); 5-13 ; Российский вестник перинатологии и педиатрии; Том 70, № 5 (2025); 5-13 ; 2500-2228 ; 1027-4065
Θεματικοί όροι: селуметиниб, neurofibromatosis type 1, plexiform neurofibromas, selumetinib, нейрофиброматоз 1 типа, плексиформные нейрофибромы
Περιγραφή αρχείου: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/2263/1633; Lammert M., Friedman J.M., Kluwe L., Mautner V.F. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005; 141(1): 71–74. DOI:10.1001/archderm.141.1.71; Evans D.G., Howard E., Giblin C., Clancy T., Spencer H., Huson S.M., Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010; 152A(2): 327–332. DOI:10.1002/ajmg.a.33139. PMID: 20082463; Uusitalo E., Leppavirta J., Koffert A., Suominen S., Vahtera J., Vahlberg T. et al. Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol. 2015; 135(3): 904–906. DOI:10.1038/jid.2014.465; Bergqvist C., Servy A., Valeyrie-Allanore L., Ferkal S., Combemale P., Wolkenstein P. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020; 15(1): 37. DOI:10.1186/s13023-020-1310-3; Pezzani L., Milani D. Epidemiology of Neurofibromatosis Type 1. In: Multidisciplinary Approach to Neurofibromatosis Type 1. Editros Tadini G., Legius E., Brems H. Springer, Cham.; 2020. DOI: org/10.1007/978-3-319-92450-2_1; Rasmussen S.A., Yang Q., Friedman J.M. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet. 2001; 68(5): 1110–1118. DOI:10.1086/320121; Masocco M., Kodra Y., Vichi M., Conti S., Kanieff M., Pace M., et al. Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995–2006). Orphanet J Rare Dis. 2011; 6: 11. DOI:10.1186/1750-1172-6-11; Anderson J.L., Gutmann D.H. Neurofibromatosis type 1. Handb Clin Neurol. 2015; 132: 75–86. DOI:10.1016/B978-0–444–62702–5.00004–4; Gutmann D.H., Ferner R.E., Listernick R.H., Korf B.R., Wolters P.L., Johnson K.J. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017; 3: 17004. DOI:10.1038/nrdp.2017.4; Anderson M.K., Johnson M., Thornburg L., Halford Z. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1–Related Plexiform Neurofibromas. Annals of Pharmacotherapy. 2021; 56(6): 716–726. DOI:10.1177/10600280211046298; Legius E., Messiaen L., Wolkenstein P., Pancza P., Avery R.A., Berman Y., et al; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021; 23(8): 1506–1513. DOI:10.1038/s41436-021-01170-5; Staser K., Yang F.C., Clapp D.W. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. Annu Rev Pathol. 2012; 7: 469–495. DOI:10.1146/annurev-pathol-011811-132441; Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K. et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol [Internet]. 2016; 131(6): 803–820. DOI:org/10.1007/s00401-016-1545-1; Suenobu S., Terashima K., Akiyama M., Oguri T., Watanabe A., Sugeno M., et al. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study. Neurooncol Adv. 2023; 5(1):vdad054. DOI:10.1093/noajnl/vdad054; Kumar V., Abbas Abul K., Aster Jon C., Debnath J., Das A. Robbins, Cotran & Kumar Pathologic basis of disease. 11th edition. Philadelphia, PA: Elsevier, 2025, 1280 p. ISBN-13 978–0443264528; Darrigo L.G. Jr, Geller M., Bonalumi Filho A., Azulay D.R. Prevalence of plexiform neurofibroma in children and adolescents with type I neurofibromatosis. J Pediatr (Rio J). 2007; 83(6): 571–573. DOI:10.2223/JPED.1718; Copley-Merriman C., Yang X., Juniper M., Amin S., Yoo H.K., Sen S.S. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic literature review. Adolesc Health Med Ther. 2021; 12: 55–66. DOI:10.2147/AHMT.S303456; Ejerskov C., Fuglsang K., Kjeldsen A.D., Ousager L.B., Daugaard T., Fagerberg C.R. Clinical characteristics and management of children and adults with neurofibromatosis type 1 and plexiform neurofibromas in Denmark: a nationwide study. Curr Treat Options Neurol. 2023; 25(1): 31–43. DOI:10.1007/s40487-022-00213-4; Mautner V.F., Hartmann M., Kluwe L., Friedrich R.E., Fünsterer C. MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology. 2006; 48(3): 160–165. DOI:10.1007/s00234-005-0033-4; Gross A.M., Singh G., Akshintala S., Baldwin A., Dombi E., et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018; 20(12): 1643–1651. DOI:10.1093/neuonc/noy067; Saleh M., Dib A., Beaini S., Saad C., Faraj S., El Joueid Y., et al. Neurofibromatosis type 1 system-based manifestations and treatments: a review. Neurol Sci. 2023; 44(6): 1931–1947. DOI:10.1007/s10072-023-06680-5; Fisher M.J., Blakeley J.O., Weiss B.D., Dombi E., Ahlawat S., Akshintala S., et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022; 24(11): 1827–1844. DOI:10.1093/neuonc/noac146; Demestre M., Herzberg J., Holtkamp N., Hagel C., Reuss D., Friedrich R.E., et al. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol. 2010; 98: 11–19. DOI:10.1007/s11060-009-0049-4.; Weiss B., Widemann B.C., Wolters P., Dombi E., Vinks A., Cantor A., et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015; 17(4): 596–603. DOI:10.1093/neuonc/nou235; Jakacki R.I., Dombi E., Steinberg S.M., Goldman S., Kieran M.W., Ullrich N.J., et al Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2017; 19(2): 289–297. DOI:10.1093/neuonc/now158; Han Y., Li B., Yu X., Liu J., Zhao W., Zhang D., Zhang J. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis. J Neurol. 2024; 271(5): 2379–2389. DOI:10.1007/s00415-024-12301-8; Casey D., Demko S., Sinha A., Mishra-Kalyani P.S., Shen Y.L., Khasar S., et al. FDA Approval Summary: Selumetinib for Plexiform Neurofibroma. Clin Cancer Res. 2021; 27(15): 4142–4146. DOI:10.1158/1078-0432.CCR-20-5032; Селуметиниб. Государственный реестр лекарственных средств. Доступно по ссылке: https://grls.rosminzdrav.ru/grls.aspx?s=%D1%81%D0%B5%D0%BB%D1%83%D0%B-C%D0%B5%D1%82%D0%B8%D0%B-D%D0%B8%D0%B1&m=mnn Ссылка активна на ноябрь 2021 г; Vaassen P., Dürr N., Röhrig A., Willing R., Rosenbaum T. Trametinib Induces Neurofibroma Shrinkage and Enables Surgery. Neuropediatrics. 2019; 50(5): 300–303. DOI:10.1055/s-0039-1691830; Moertel C.L., Hirbe A.C., Shuhaiber H.H., Bielamowicz K., Sidhu A., Viskochil D., et al; ReNeu Trial Investigators; Re-Neu Study Investigators. ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma. J Clin Oncol. 2025; 43(6): 716–729. DOI:10.1200/JCO.24.01034; Gross A.M., Dombi E., Wolters P.L., Baldwin A., Dufek A., Herrera K., et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro Oncol. 2023; 25(10): 1883–1894. DOI:10.1093/neuonc/noad086; Koselugo (selumetinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020. 28p. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000l-bl.pdf. Ссылка активна на август 2025; Campagne O., Yeo K.K., Fangusaro J., Stewart C.F. Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. Clin Pharmacokinet. 2021; 60(3): 283–303. DOI:10.1007/s40262-020-00967-y; Gross A.M., Achée C., Hart S.E., Brewer L., Baldwin A., Wolters P.L., et al; SPRINT study team. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Future Oncol. 2024; 20(14): 877–890. DOI:10.2217/fon-2023-0565; Adeyemi A., Gross A.M., Baldwin A., Dombi E., Widemann B.C., Sint K.J. Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm. Neurooncol Adv. 2025; 7(1):vdaf101. DOI:10.1093/noajnl/vdaf101; Gross A.M., Wolters P.L., Dombi E., Baldwin A., Whitcomb P., Fisher M.J., et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020; 382(15): 1430–1442. DOI:10.1056/NEJMoa1912735; Gross A.M., Glassberg B., Wolters P.L., Dombi E., Baldwin A., Fisher M.J. et al. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro Oncol [Internet]. 2022; 24(11): 1978–1988. DOI:10.1093/neuonc/noac109; Ratner N., Miller S.J. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer [Internet]. 2015; 15(5): 290–301. DOI:10.1038/nrc3911; Deming D.A., Cavalcante L.L., Lubner S.J., Mulkerin D.L., Lo-Conte N.K., Eickhoff J.C. et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs [Internet]. 2016; 34(2): 168–175. DOI:org/10.1007/s10637–015–0314; Dombi E., Baldwin A., Marcus L.J., Fisher M.J., Weiss B., Kim A. et al. Activity of Selumetinib in neurofibromatosis type 1–related plexiform neurofibromas. N Engl J Med [Internet]. 2016; 375(26): 2550–2560. DOI:10.1056/NEJMoa1605943; Schalkwijk S., Zhou L., Cohen-Rabbie S., Jain L., Freshwater T., So K., et al. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. Cancer Chemother Pharmacol. 2021; 88(2): 189–202. DOI:10.1007/s00280-021-04274-6; Espírito Santo V., Passos J., Nzwalo H., Carvalho I., Santos F., Martins C., et al. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. J Neurooncol. 2020; 147(2): 459–463. DOI:10.1007/s11060-020-03443-6; Jackson S., Baker E.H., Gross A.M., Whitcomb P., Baldwin A., Derdak J., et al. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neurooncol Adv. 2020; 2(1):vdaa095. DOI:10.1093/noajnl/vdaa095; Metrock L.K., Lobbous M., Korf B. An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromas, Expert Review of Precision Medicine and Drug Development. 2021; 6: 4, 239–246. DOI:10.1080/23808993.2021.1917989; Perreault S., Larouche V., Tabori U., Hawkin C., Lippé S., Ellezam B., et al. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer. 2019; 19(1): 1250. DOI:10.1186/s12885-019-6442-2; Dai Y., Choi C., Wiltsie L., Callahan A. Selumetinib in the treatment of orbital plexiform neurofibroma: a case report. Ophthalmic Plast Reconstr Surg. 2023; 39(3): e75–e78. DOI:10.1097/IOP.0000000000002330; Jauregui R., Garcia M., Jain A., Segal D. Selumetinib halts progression of Orbital/Periorbital plexiform neurofibromas in neurofibromatosis type 1 (P4–5.007). Neurology. 2024; 102(17_supplement_1). DOI:10.1212/wnl.0000000000204446; Baldo F., Magnolato A., Barbi E., Bruno I. Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change. BMC Pediatr [Internet]. 2021; 21(1): 67. DOI:10.1186/s12887-021-02530-5; Volontè M., Isoletta E., Gordon S., Foiadelli T., Bassanese F., Rossi A. et al. Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: good results with doxycycline. Dermatol Ther [Internet]. 2022; 35(8): e15607. DOI:10.1111/dth.15607; Xiong R., Lei J., Wang L., Zhang S., Liu H., Wang H., et al. Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example. Front Pharmacol. 2024; 15: 1432759. DOI:10.3389/fphar.2024.1432759; Liu F., Su H., Wei W. Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system. Sci Rep. 2025; 15(1): 9218. DOI:10.1038/s41598-025-92741-y; Caiffa T., Tessitore A., Magnolato A., Petz M., Bobbo M., Chicco D., et al. Characterization of Cardiac Function by Echocardiographic Global Longitudinal Strain in a Cohort of Children with Neurofibromatosis Type 1 Treated with Selumetinib. Paediatr Drugs. 2023; 25(2): 217–224. DOI:10.1007/s40272-022-00551-w; Пивоварова А.М., Дорофеева М.Ю., Забродина А.Р. Боченков С.В., Григорьева А.В., Горчханова З.К., Воронина В.Р. Лекарственная терапия плексиформных нейрофибром при нейрофиброматозе 1-го типа. Возможные нежелательные явления и их коррекция. Русский журнал детской неврологии 2024; 19(2): 8–19.; Dinikina Y., Dorofeeva M., Nakhusheva F. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas that can’t be removed by surgery, and impact on how the condition affects caregivers: a plain language summary. J Comp Eff Res. 2025; 14(3):e240184. DOI:10.57264/cer-2024-0184
-
2Academic Journal
Συγγραφείς: A. M. Pivovarova, M. Yu. Dorofeeva, A. R. Zabrodina, S. V. Bochenkov, A. V. Grigoryeva, Z. K. Gorchkhanova, V. R. Voronina, А. М. Пивоварова, М. Ю. Дорофеева, А. Р. Забродина, С. В. Боченков, А. В. Григорьева, З. К. Горчханова, В. Р. Воронина
Πηγή: Russian Journal of Child Neurology; Том 19, № 2 (2024); 8-19 ; Русский журнал детской неврологии; Том 19, № 2 (2024); 8-19 ; 2412-9178 ; 2073-8803
Θεματικοί όροι: профилактика осложнений, plexiform neurofibromas, selumetinib, adverse events, toxicity control, prevention of complications, плексиформные нейрофибромы, селуметиниб, нежелательные явления, контроль токсичности
Περιγραφή αρχείου: application/pdf
Relation: https://rjdn.abvpress.ru/jour/article/view/471/317; Инструкция по медицинскому применению лекарственного препарата Коселуго® (селуметиниб) ЛП-007563 от 01.11.2021.; Blakeley J., Plotkin S. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwan-nomatosis. Neuro Oncol 2016;18(5):624–38. DOI:10.1093/neuonc/nov200; Carton С., Gareth Evans D., Blanco I. et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. E Clin Med 2023;56:101818. DOI:10.1016/j.eclinm.2022.101818; Cimino P., Gutmann D. Neurofibromatosis type 1. Handb Clin Neurol 2018;148:799–811. DOI:10.1016/B978-0-444-64076-5.00051-X; Dagher S., Blom A., Chabanol H. et al. Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management. Int J Womens Dermatology 2021;7(5):615–24. DOI:10.1016/j.ijwd.2021.09.009; Dombi E., Andrea Baldwin A., Marcus L. et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 2016;375(26):2550–60. DOI:10.1056/NEJMoa1605943; Farschtschi S., Mautner V., Lawson A. et al. The neurofibromatoses. Deutsches Arzteblatt Int 2020;117(20):354. DOI:10.3238/arztebl.2020.0354; Gross A.M., Wolters P.L., Dombi E. et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro Oncol 2023;25(10):1883–94. DOI:10.1093/neuonc/noad086; Gross A.M., Wolters P.L., Dombi E. et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020;382:1430–42. DOI:10.1056/NEJMoa1912735; Gutmann D., Ferner R., Listernick R. et al. Neurofibromatosis type 1. Nat Rev Dis Primers 2017;3:17004. DOI:10.1038/nrdp.2017.4; Hirbe A., Gutmann D. et al. Neurofibromatosis type 1: A multidisciplinary approach to care. Lancet Neurol 2014;13(8):834–43. DOI:10.1016/S1474-4422(14)70063-8; Klesse L., Jordan J., Radtke H. et al. The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist 2020;25(7):e1109–16. DOI:10.1634/theoncologist.2020-0069; Koczkowska M., Chen Y., Callens T. Genotype-phenotype correlation in NF1: Evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844–848. Am J Hum Genet 2018;102(1):69–87. DOI:10.1016/j.ajhg.2017.12.001; NCI CTCAE v. 5.0. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0/Archive/CTCAE_5.0_2009-05-29_QuickReference_8.5x11.pdf.; Needle M.N., Cnaan A., Dattilo J. et al. Prognostic signs in the surgical management of plexiform neurofibroma: The Children’s Hospital of Philadelphia experience, 1974–1994. J Pediatr 1997; 131:678–8. DOI:10.1016/s0022-3476(97)70092-1; Nguyen R., Ibrahim С., Friedrich R. et al. Growth behavior of plexiform neurofibromas after surgery. Genet Med 2013;15:691–7. DOI:10.1038/gim.2013.30; Nishio M., Kato T., Toyozawa R. et al. Management of peripheral edema in patients with MET exon 14-mutated non-small cell lung cancer treated with small molecule MET inhibitors. Target Oncol 2022;17(5):597–604. DOI:10.1007/s11523-022-00912-y; Prudner B., Ball T., Rathore R. et al. Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives. Neurooncol Adv 2019;2(Suppl 1):i40–9. DOI:10.1093/noajnl/vdz047; Scheer M., Leisz, S., Sorge E. et al. Neurofibromatosis type 1 gene alterations define specific features of a subset of glioblastomas. Int J Mol Sci 2022;23(1):352. DOI:10.3390/ijms23010352; Volonte M., Esoletta E., Gordon S. et al. Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline. Dermatol Ther 2022;35:e15607. DOI:10.1111/dth.15607; Yang Y., Liu Y., Sun X. et al. Risk of peripheral edema in cancer patients treated with MEK inhibitors: A systematic review and meta-analysis of clinical trials. Curr Med Res Opin 2017;33(9):1663–75. DOI:10.1080/03007995.2017.1349657; Yap Y.-S., McPherson J.R., Ong C.-K. et al. The NF1 gene revisited – from bench to bedside. Oncotarget 2014;5(15):5873–92. DOI:10.18632/oncotarget.2194; https://rjdn.abvpress.ru/jour/article/view/471